DelveInsight Business Research, LLP: TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...
Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In March 2025, Akeso initiated an open-label, Phase Ib/II study involving patients diagnosed with acute myeloid leukemia (AML ...
TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...
The Manila Times2d
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
Purple Biotech's growing intellectual property portfolio for NT219 in combination with anti-cancer standard-of-care therapies ...
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Our team’s strong focus and execution over the last twelve months lay the groundwork for a potential breakthrough year for iTeos in 2025. As we advance multiple trials evaluating belrestotug + ...
TMCnet3d
IO Biotech Reports 2024 Business Highlights
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
BALVERSA Adoption On The Rise: Meeting Unmet Needs In Advanced Urothelial Cancer | Delveinsight
BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...
Microbiome Disease Clinical Trial Analysis: Key Insights Into Rich Pipeline Featuring 140+ Companies And 180+ Therapies | Delveinsight
The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-b ...
Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data reado ...